In Vitro Activity of HSR-903, a New Oral Quinolone, against Bacteria Causing Respiratory Infections
AUTOR(ES)
Watanabe, Akira
FONTE
American Society for Microbiology
RESUMO
The in vitro activity of HSR-903, an oral quinolone, against 196 recent clinical isolates of respiratory pathogens was evaluated. HSR-903 was 2 to 32 times more active than ofloxacin, ciprofloxacin, and sparfloxacin against Staphylococcus aureus, including methicillin-resistant strains, and Streptococcus pneumoniae and was at least as active as the other quinolones against gram-negative pathogens.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=89361Documentos Relacionados
- In vitro activity of HSR-903, a new quinolone.
- In Vivo Activity of HSR-903, a New Fluoroquinolone, against Respiratory Pathogens
- In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic.
- In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.
- Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis.
